ArticleDer Nervenarzt2019
[Characteristics and dynamics of inpatient treatment of patients with Parkinson's disease in Germany : Analysis of 1.5 million patient cases from 2010 to 2015].
Article in Der Nervenarzt, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 22 citations in OpenAlex.
- Parkinson´s day-clinic: which patients should be selected and what services should be offered for successful therapy?Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- Searching for a needle in a haystack-ambulatory research in Parkinson's disease in Germany.Frontiers in aging neuroscience · 2026Article
- Trends and Sex Differences in Hospitalizations and Mortality in Parkinson's Disease in Spain (2010-2019): A Nationwide Population-Based Study.Journal of clinical medicine · 2023Article
- [Treatment practice of patients with Parkinson's disease in Saxony : A secondary data-based analysis of utilization in the observation period 2011-2019].Der Nervenarzt · 2022Article
- [Relevance of COMT inhibitors in the treatment of motor fluctuations].Der Nervenarzt · 2022Review
- Clinical Profiles and Mortality of COVID-19 Inpatients with Parkinson's Disease in Germany.Movement disorders : official journal of the Movement Disorder Society · 2021Article
- Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis.Journal of neural transmission (Vienna, Austria : 1996) · 2021Article
- Specialized Staff for the Care of People with Parkinson's Disease in Germany: An Overview.Journal of clinical medicine · 2020Review
- Hospitalization Rates and Comorbidities in Patients with Progressive Supranuclear Palsy in Germany from 2010 to 2017.Journal of clinical medicine · 2020Article
- [Care of patients with Parkinson's disease in Germany].Der Nervenarzt · 2020Review
- Recommendations for Standards of Network Care for Patients with Parkinson's Disease in Germany.Journal of clinical medicine · 2020Review
- Letter to the editor: risk comorbidities of COVID-19 in Parkinson's disease patients in Germany.Neurological research and practice · 2020Article
- Dynamics of device-based treatments for Parkinson's disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation.Journal of neural transmission (Vienna, Austria : 1996) · 2019Article
- Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.Drugs & aging · 2019Review
- Article
- The Hamburg Parkinson day-clinic: a new treatment concept at the border of in- and outpatient care.Journal of neural transmission (Vienna, Austria : 1996) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease is the most common neurodegenerative movement disorder and the fastest-growing neurological disease in the world. The diagnostic spectrum, demographic characteristics, comorbidities and case number developments of inpatient treatment in Germany with resulting implications for patient care have so far been insufficiently investigated.
methodsData from the diagnosis-related groups (DRG) statistics were analyzed in patients with a main and secondary diagnosis of primary Parkinson's syndrome (PS), secondary PS or other degenerative disease of the basal ganglia. For the reporting years 2010-2015, the dataset comprised 1,520,366 patient cases from 413 districts/independent cities throughout Germany.
resultsIn 2015, mostly patients with moderate and severe primary PS were hospitalized (64.7%) often exhibiting motor fluctuations as well as marked medical and psychiatric comorbidities. Vascular parkinsonism was the most frequent secondary PS (36.6%) and progressive supranuclear palsy was the leading diagnosis in the other disorders of the basal ganglia (51.9%). Primary PS as a secondary diagnosis was found in many internal medicine hospitalizations. The inpatient case numbers for primary PS increased significantly from the years 2010 to 2015 and rural regions were particularly affected.
conclusionThe number of inpatient cases of Parkinson's disease is greatly increasing in Germany and mainly affects patients with severe motor complications and secondary parkinsonian syndromes. Particularly in rural areas, there is a risk of overburdening the treatment infrastructure, so that both outpatient and inpatient sectors must be strengthened. A limitation of the study is the analysis of only DRG coded data, whose quality could be improved in subsequent examinations by comparison with the current diagnostic criteria of the specialist societies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.